Company news
Moderna, Inc. (NASDAQ:MRNA) news
Every Moderna, Inc. press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
Moderna Announces Pricing of Upsized $2.6 Billion Offering of Convertible Senior Notes
August 28, 2026
Moderna Receives U.S. FDA Approval for Updated 2026-2027 COVID-19 Vaccines
August 27, 2026
Moderna Announces Proposed Private Placement of $2.0 Billion of Convertible Senior Notes
August 27, 2026
Moderna Receives U.S. FDA Approval for Influenza Vaccine mFLUSIVA
August 5, 2026
Moderna Announces Initiation of Phase 1 Clinical Trial of mRNA-1469, Moderna's Investigational Vaccine Against Bundibugyo Ebolavirus
August 4, 2026
Moderna Reports Second Quarter 2026 Financial Results and Provides Business Updates
July 31, 2026
Moderna Announces First Participant Dosed in Phase 1 Clinical Trial Evaluating Investigational Tumor-Targeted Cancer Antigen Therapy in S...
July 16, 2026
Moderna to Report Second Quarter 2026 Financial Results on Friday, July 31, 2026
July 9, 2026
Moderna Appoints Michael McDonnell to Board of Directors
July 8, 2026
Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 2, 2026
Moderna Announces FDA Advisory Committee Votes Unanimously in Favor of the Benefit-Risk Profile of mRNA-1010, an Investigational Seasonal...
June 18, 2026
Moderna to Host Investor Event - Science Day
June 17, 2026
Moderna Announces Organizational Changes to Prepare for Multiple Product Launches in 2027 and 2028
June 16, 2026
Moderna and the University of Oxford Receive UK Authorization to Begin Phase 1/2 Study of Investigational mRNA Cancer Vaccine for People ...
June 8, 2026
Moderna Launches Moderna Direct with “eCommerce Powered by FFF Enterprises™”
June 2, 2026
Moderna to Present at Upcoming Conference in June 2026
June 2, 2026
Moderna and CEPI Expand Strategic Collaboration to Advance Potential Vaccine Against Bundibugyo Ebolavirus
June 1, 2026
Moderna and Merck Present 5-Year Data for Intismeran Autogene in Combination With KEYTRUDA (pembrolizumab) in Patients With High-Risk Sta...
June 1, 2026
Moderna Recognized by TIME as One of the World's Most Impactful Companies
May 12, 2026
Moderna Announces New England Journal of Medicine Publication of Pivotal Phase 3 Clinical Safety and Efficacy Data for Its Investigationa...
May 6, 2026
Moderna : Presentation (Moderna 1Q26 Earnings Presentation FINAL)
May 4, 2026
Moderna Reports First Quarter 2026 Financial Results and Provides Business Updates
May 1, 2026
Moderna Announces Initiation of Phase 3 Study of Investigational mRNA Pandemic Influenza Vaccine Candidate
April 21, 2026
Moderna to Present Phase 1/2 Data on Its Investigational Cancer Antigen Therapy mRNA-4359 as First-Line Therapy in Combination with Pembr...
April 17, 2026
Moderna to Report First Quarter 2026 Financial Results on Friday, May 1, 2026
April 15, 2026
Moderna to Present Revaccination Data for Its Investigational Seasonal Influenza Vaccine and for mRESVIA at ESCMID 2026
April 6, 2026
Moderna Resolves Global Patent Litigation with Arbutus/Genevant
March 3, 2026
European Medicines Agency's Committee for Medicinal Products for Human Use Adopts Positive Opinion Recommending Marketing Authorization o...
February 27, 2026
Moderna to Present at Upcoming Conferences in March 2026
February 19, 2026
Moderna Announces the U.S. Food and Drug Administration will Initiate the Review of Its Investigational Seasonal Influenza Vaccine Submis...
February 18, 2026
Moderna Receives European Commission Marketing Authorization for COVID-19 Vaccine mNEXSPIKE
February 17, 2026
Moderna Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Business Updates
February 13, 2026
Moderna to Enter into Long-Term Strategic Agreement with the Government of Mexico
February 10, 2026
Moderna Receives Refusal-to-File Letter from the U.S. Food and Drug Administration for Its Investigational Seasonal Influenza Vaccine, mR...
February 10, 2026
Defiance Launches MRNX: The First Daily 2X Long ETF for Moderna, Inc.
February 4, 2026
How Moderna Uses Decision Intelligence to Enable an Autonomous Cold Chain, Upcoming Webinar Hosted by Xtalks
February 3, 2026
Dr. David Berman to Join Moderna as Chief Development Officer
January 30, 2026
Moderna Announces Strategic Collaboration with Recordati to Globally Commercialize Investigational Propionic Acidemia Therapeutic (mRNA-3...
January 29, 2026
Moderna to Report Fourth Quarter 2025 Financial Results on Friday, February 13, 2026
January 26, 2026
Moderna & Merck Announce 5-Year Data for Intismeran Autogene in Combination With KEYTRUDA(R) (pembrolizumab) Demonstrated Sustained Impro...
January 20, 2026
Moderna Provides Business and Pipeline Updates at 44th Annual J.P. Morgan Healthcare Conference
January 12, 2026
Moderna Announces Global Regulatory Submissions for Its Investigational Seasonal Influenza Vaccine
January 5, 2026
CEPI to Fund Pivotal Phase 3 Trial for Moderna's mRNA Pandemic Influenza Vaccine Candidate
December 18, 2025
Moderna to Present at the 44th Annual J.P. Morgan Healthcare Conference
December 17, 2025
EMA Committee for Medicinal Products for Human Use Adopts Positive Opinion Recommending Authorization of Moderna's mNEXSPIKE (COVID-19 Va...
December 15, 2025
Eikon Therapeutics Announces the Election of David W. Meline to its Board of Directors
December 2, 2025
Moderna Secures $1.5 Billion Five-Year Credit Facility from Ares Management
November 20, 2025
Moderna Analyst Day Highlights Pipeline Progress and Business Strategy Updates
November 20, 2025
Moderna Expands U.S. Manufacturing with Onshoring of Drug Product Capabilities
November 19, 2025
Moderna to Present at Upcoming Piper Sandler's 37th Annual Healthcare Conference on December 2, 2025
November 18, 2025